| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Abiratone |
| Brand | Zytiga® |
| Indication | Treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated |
| Assessment Process | |
| Rapid review commissioned | 03/01/2013 |
| Rapid review completed | 01/02/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 26/09/2013 |
| NCPE assessment completed | 07/03/2014 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
